ATE337010T1 - Desinfizierende und solubilisierende steroidzusammensetzungen - Google Patents
Desinfizierende und solubilisierende steroidzusammensetzungenInfo
- Publication number
- ATE337010T1 ATE337010T1 AT02769298T AT02769298T ATE337010T1 AT E337010 T1 ATE337010 T1 AT E337010T1 AT 02769298 T AT02769298 T AT 02769298T AT 02769298 T AT02769298 T AT 02769298T AT E337010 T1 ATE337010 T1 AT E337010T1
- Authority
- AT
- Austria
- Prior art keywords
- disinfecting
- solubilizing
- steroid compositions
- prednisolone
- cyclodextrin
- Prior art date
Links
- 230000000249 desinfective effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003381 solubilizing effect Effects 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 4
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 abstract 2
- 229960005205 prednisolone Drugs 0.000 abstract 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 2
- 229960002800 prednisolone acetate Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28933701P | 2001-05-07 | 2001-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE337010T1 true ATE337010T1 (de) | 2006-09-15 |
Family
ID=23111093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02769298T ATE337010T1 (de) | 2001-05-07 | 2002-04-29 | Desinfizierende und solubilisierende steroidzusammensetzungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20020198174A1 (https=) |
| EP (2) | EP1702619A2 (https=) |
| JP (1) | JP2004529167A (https=) |
| AT (1) | ATE337010T1 (https=) |
| AU (1) | AU2002308544B2 (https=) |
| CA (1) | CA2446528A1 (https=) |
| DE (1) | DE60214157T2 (https=) |
| ES (1) | ES2269763T3 (https=) |
| WO (1) | WO2002089815A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU757896B2 (en) * | 1998-09-02 | 2003-03-13 | Allergan, Inc. | Preserved cyclodextrin-containing compositions |
| US20040152664A1 (en) * | 1998-09-02 | 2004-08-05 | Allergan, Inc. | Prednisolone compositions |
| WO2004069280A1 (en) * | 2003-02-06 | 2004-08-19 | Cipla Ltd | Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent |
| US20050085446A1 (en) * | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| AU2011235943B2 (en) * | 2003-12-31 | 2014-06-26 | Cydex Pharmaceuticals, Inc | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| RU2006127432A (ru) * | 2003-12-31 | 2008-02-10 | Сайдекс, Инк. (Us) | Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид, полученная из единичной дозы суспензии |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US7892483B2 (en) | 2004-03-12 | 2011-02-22 | Cipla Limited | Sterilization process |
| US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US6969706B1 (en) * | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
| EP1761283A2 (en) * | 2004-06-07 | 2007-03-14 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
| US20060006361A1 (en) * | 2004-07-08 | 2006-01-12 | Joseph Callerame | Clathrate of chlorine dioxide |
| US20070197487A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an increased lung deposition |
| US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
| US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
| US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
| US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
| US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
| US20070178050A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an increased lung depositon |
| US20070149480A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| TW200800177A (en) * | 2006-02-14 | 2008-01-01 | Wyeth Corp | Aqueous pharmaceutical formulations of ERβ selective ligands |
| US20070238789A1 (en) * | 2006-03-31 | 2007-10-11 | Chin-Ming Chang | Prednisolone acetate compositions |
| US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| EP2173169B1 (en) * | 2007-06-28 | 2014-05-21 | CyDex Pharmaceuticals, Inc. | Nasal delivery of aqueous corticosteroid solutions |
| US8040246B2 (en) * | 2007-12-04 | 2011-10-18 | Avaya Inc. | Systems and methods for facilitating a first response mission at an incident scene |
| US8545554B2 (en) | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| BR112017002466A2 (pt) | 2014-08-08 | 2017-12-05 | Forsight Vision4 Inc | formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| JP7138103B2 (ja) * | 2016-11-29 | 2022-09-15 | オキュリス エスエー | 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造 |
| EP4670738A3 (en) | 2019-07-01 | 2026-03-04 | Oculis Operations Sàrl | Method for stabilizing the ph of an aqueous composition comprising a drug |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU185926B (en) * | 1979-09-27 | 1985-04-28 | Agostne Kahan | Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives |
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| DE3612538A1 (de) * | 1986-04-14 | 1987-10-15 | Dispersa Ag | Stabilisierung von quecksilberhaltigen konservierungsmitteln in augentropfen |
| US4822819A (en) * | 1986-11-07 | 1989-04-18 | Alcon Laboratories, Inc. | Use of trimoprostil and derivatives in glaucoma therapy |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5504113A (en) * | 1994-03-02 | 1996-04-02 | Allergan, Inc. | Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug |
| WO1996011003A1 (en) * | 1994-10-10 | 1996-04-18 | Novartis Ag | Ophthalmic and aural compositions containing diclofenac potassium |
| JP3170619B2 (ja) * | 1995-04-20 | 2001-05-28 | 参天製薬株式会社 | 有機アミンを配合したプラノプロフェン点眼液 |
| US5744154A (en) * | 1995-09-06 | 1998-04-28 | Laboratoire Chauvin S.A. | Ready-to-use indomethacin-based eye lotion |
| JP3883739B2 (ja) * | 1998-05-22 | 2007-02-21 | 株式会社メニコン | コンタクトレンズ用殺菌液 |
| US6486208B1 (en) * | 1998-09-25 | 2002-11-26 | Alcon Laboratories, Inc. | Sustained release, and comfortable opthalmic composition and method for ocular therapy |
-
2002
- 2002-04-12 US US10/121,076 patent/US20020198174A1/en not_active Abandoned
- 2002-04-29 CA CA002446528A patent/CA2446528A1/en not_active Abandoned
- 2002-04-29 JP JP2002586950A patent/JP2004529167A/ja active Pending
- 2002-04-29 WO PCT/US2002/013701 patent/WO2002089815A2/en not_active Ceased
- 2002-04-29 AU AU2002308544A patent/AU2002308544B2/en not_active Ceased
- 2002-04-29 AT AT02769298T patent/ATE337010T1/de not_active IP Right Cessation
- 2002-04-29 EP EP06006547A patent/EP1702619A2/en not_active Withdrawn
- 2002-04-29 ES ES02769298T patent/ES2269763T3/es not_active Expired - Lifetime
- 2002-04-29 EP EP02769298A patent/EP1385528B1/en not_active Expired - Lifetime
- 2002-04-29 DE DE60214157T patent/DE60214157T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1061520A1 (en) | 2004-09-24 |
| DE60214157T2 (de) | 2007-07-12 |
| WO2002089815A2 (en) | 2002-11-14 |
| DE60214157D1 (de) | 2006-10-05 |
| US20020198174A1 (en) | 2002-12-26 |
| EP1702619A2 (en) | 2006-09-20 |
| ES2269763T3 (es) | 2007-04-01 |
| EP1385528B1 (en) | 2006-08-23 |
| CA2446528A1 (en) | 2002-11-14 |
| WO2002089815A3 (en) | 2003-02-20 |
| AU2002308544B2 (en) | 2006-09-07 |
| EP1385528A2 (en) | 2004-02-04 |
| JP2004529167A (ja) | 2004-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE337010T1 (de) | Desinfizierende und solubilisierende steroidzusammensetzungen | |
| ATE459313T1 (de) | Medizinische vorrichtungen | |
| CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
| TR200103575T2 (tr) | Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler | |
| PL374523A1 (pl) | Koniugaty pochodna kalicheamycyny-nośnik | |
| CY1107325T1 (el) | Διαδικασια για την επικαλυψη ιατρικων συσκευων χρησιμοποιωντας υπepκρισιμο διοξειδιο του ανθρακα | |
| ID26989A (id) | Smilagenin dan anzurogenin-d untuk pengobatan penyakit alzheimer | |
| AU2003247798A1 (en) | Nozzles and components thereof and methods for making the same | |
| WO2002061027A8 (en) | Nanozeolites for malodor control | |
| ATE392197T1 (de) | Medizinische vorrichtungen und herstellungsverfahren dafür | |
| DE60331458D1 (de) | Kombinationschemotherapie mit chlorotoxin | |
| NL300364I2 (nl) | Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie | |
| ATE410082T1 (de) | Desodorisierungszusammensetzung für tabakgeruch, desodorisierungsmittel für tabakgeruch und zigaretten- und tabakpackung mit vermindertem sekundärrauchgeruch | |
| DE60101232D1 (de) | Elektronenemittierende Quelle, Baugruppe und Verfahren zu deren Herstellung | |
| CY1108281T1 (el) | 17-α-υποκατασταθεισα-11-β-υποκατασταθεισα-4-αρυλ και 21-υποκατασταθεισα 19-νορπρεγναδιενοδιονη ως νεοι αντι-προεμμηνορροϊκοι παραγοντες. | |
| NL1027052A1 (nl) | Operationele versterker van rail-naar-rail van klasse AB. | |
| ATE472598T1 (de) | Cd4+cd25+ regulatorische t-zellen aus menschlichem blut | |
| ATE353909T1 (de) | 3-stickstoff-6,7-dioxygenierte steroid verbindungen und verwendungen davon | |
| MXPA03006933A (es) | Aparato y metodo para desorodizar y refrescar el ambiente. | |
| DE60232660D1 (de) | Humane dr4-antikörper und deren anwendungen | |
| PT1560812E (pt) | Compostos de aminociclohexil eter e suas utilizacoes | |
| DE60228184D1 (de) | Verfahren zur Herstellung von Chondroitinsulfaten aus K4-Polysaccharid und so hergestellte Produkte | |
| CY1112591T1 (el) | Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης | |
| ATE264299T1 (de) | Peroxycarbonsäure und ihre wässrigen zusammensetzungen | |
| ATE375359T1 (de) | Aminosterolderivate und ihre verwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |